Evidence map›Paper›PMID 25387088›Full record

Trial reportBone marrow transplantation2015

Trends in autologous hematopoietic cell transplantation for multiple myeloma in Europe: increased use and improved outcomes in elderly patients in recent years.

H W Auner, R Szydlo, J Hoek, H Goldschmidt, A M Stoppa, G J Morgan, P Moreau, M Attal, G Marit, N Russell and 6 more

Abstract readClinical TrialMulticenter Study
PubMed Publisher
In one paragraph

Trial report in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed
7.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 121 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Melphalan 140 mg/mHaematologica · 2018
    Trial
  5. Trial
  6. Trial
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Fitness and frailty in myeloma.Hematology. American Society of Hematology. Education Program · 2022
    Review
  13. Article
  14. Article
  15. Trends in Late Mortality and Life Expectancy After Autologous Blood or Marrow Transplantation Over Three Decades: A BMTSS Report.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022
    Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 14 institutions in 5 countries.

H W AunerDepartment of Medicine, Imperial College London, London, UK.
R SzydloDepartment of Medicine, Imperial College London, London, UK.
J HoekLeiden University Medical Centre, Leiden, The Netherlands.
H GoldschmidtMedizinische Klinik V, University Hospital Heidelberg, Heidelberg, Germany.
A M StoppaInstitut Paoli Calmette, Marseille, France.
G J MorganThe Royal Marsden Hospital, London, UK.
P MoreauCentre Hospitalier Universitaire, Nantes, France.
M AttalCentre Hospitalier Universitaire, Toulouse, France.
G MaritCentre Hospitalier Universitaire, Bordeaux, France.
N RussellNottingham City Hospital, Nottingham, UK.
M BruneSahlgrenska University Hospital, Göteborg, Sweden.
G CookSt James's Institute of Oncology, Leeds, UK.
P SonneveldDaniel den Hoed Cancer Centre, Rotterdam, The Netherlands.
S SchönlandMedizinische Klinik V, University Hospital Heidelberg, Heidelberg, Germany.
L GarderetDepartment of Haematology, Hopital Saint-Antoine, Paris, France.
N KrögerUniversitätsklinikum Hamburg-Eppendorf, Hamburg, Germany.
Imperial College London · GBUniversity Hospital Heidelberg · DECentre Hospitalier Universitaire de Bordeaux · FRCentre Hospitalier Universitaire de Nantes · FRCentre Hospitalier Universitaire de Toulouse · FRHôpital Saint-Antoine · FRInstitut Paoli-Calmettes · FRLeiden University Medical Center · NLNottingham City Hospital · GBRotterdam University of Applied Sciences · NLRoyal Marsden Hospital · GBSahlgrenska University Hospital · SESt James's University Hospital · GBUniversity Medical Center Hamburg-Eppendorf · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autologous hematopoietic cell transplantation (AHCT) is a standard of care in multiple myeloma (MM) patients aged <65 years. To understand age-related trends in utilisation and outcome of AHCT, we analysed 53 675 MM patients who underwent a first AHCT in 31 European countries between 1991 and 2010. The number of patients undergoing AHCT increased for all age groups (<40, 40-49, 50-59, 60-64, 65-69 and ⩾70 years) throughout the observation period. The highest increase was observed for patients aged ⩾65 years, who accounted for 3% of AHCTs in 1991-1995 and for 18.8% of AHCTs in 2006-2010. Risk factors associated with survival over the entire observation period (P<0.001) were calendar period, remission status at AHCT, gender, disease duration before AHCT and age. Survival improved considerably more in older than in younger patients in recent years. In 2006-2010, median 2- and 5-year post-transplant survival ranged from 85.9 and 61.5% in patients <40 years to 80.2 and 49.7% in those ⩾70 years. All-cause day-100 mortality decreased throughout the observation period to ⩽2.4% for all age groups in 2006-2010. The results of this study demonstrate increased utilisation and safety of AHCT with improved post-transplant survival particularly in elderly MM patients in recent years in Europe.

Indexed as

AdultAgedAge FactorsAutograftsDisease-Free SurvivalEuropeFemaleHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedMultiple MyelomaRegistriesSurvival Rate

Identifiers

PMID25387088
OpenAlexW2061230659

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.